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Abstract 
 
The investigation of dermatological conditions embraces the concept of a clinico-
pathological correlation. The studies into cutaneous T cell lymphoma (CTCL) and 
malignant melanoma (MM), presented here involved predominantly 
immunocytochemical procedures and relate to the investigations into AP-1 
protein expression in CTCL and melanocyte activation antigens in MM. 
Results: Findings indicate that expression of AP-1 proteins differs not only 
according to type of CTCL but also according to stages of tumour progression. In 
MM activation antigen expression varies with tumour metastasis. 
Consideration of the role of techniques in terms of sensitivity and specificity form 
a pivitol component in the evaluation of tumour antigen expression. 
 
Key words: Cutaneous T cell lymphoma (CTCL), malignant melanoma (MM), 
immunocytochemistry (IMC).
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Chapter 1 Introduction 
 
With all dermatological conditions, there is a close link between the clinical 
manifestation of the disease and the histopathological appearance under the 
microscope. Within the field of dermatology, this clinico-pathological correlation 
has developed to such a high degree that it is now possible to identify stages of 
clinical disease progression with clearly defined histopathological observations. 
Examples of pathological conditions where this is possible are malignant disease 
such as cutaneous T cell lymphoma (CTCL) and also entities which do not 
necessarily exhibit all the characteristic features that are associated with 
malignant disease, either clinically or histologically; such as lymphomatoid 
papulosis (LyP).  
 
The World Health Organisation (WHO) in conjunction with the European 
Organisation for Research and Treatment of Cancer (EORTC) have classified 
LyP as a low grade cutaneous T cell lymphoma (Willemze et al 2005). This 
lymphoma presents as recurrent, self healing, papulonecrotic or nodular skin 
lesion(s), which can present with histological features indicative of CD30 + 
malignant lymphoma or mycosis fungoides (MF), other forms of cutaneous T cell 
lymphoma. It is also a well-documented fact that there is a close association with 
patients who have LyP and other forms of CTCL not only histopathologically but 
also clinically. This suggests a common genetic link. Evidence for this comes 
from reports of patients exhibiting more than one form of cutaneous lymphoma 
contiguously. Thus patients may present with MF, Sezary syndrome (SS), or 
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Hodgkins disease and LyP, co- existing as clinically distinct cutaneous 
lymphomas (Beljaards and Willemze 1992). These appearances are not 
sequential, in other words patients may present with LyP first then MF or SS or 
CD30+ anaplastic large cell lymphoma, or conversely they may present with MF 
and then LyP or finally they may present with both conditions at the same time 
(Basarab et al 1998).  
 
The fundamental observation with patients who present with LyP is that only up 
to 20% of them develop a second form of CTCL (Bekkenk et al 2000). The 
remaining 80-90% may have recurrent episodes of self healing lesions which 
may occur over many decades and may last for months or years and which often 
result in superficial hypopigmented scars, without any significant life threatening 
complications.  
 
Histopathologically, LyP is classified under three distinct subtypes (types A, B 
and C). These are defined by the appearance of atypical population of T cells. 
Types A and C resemble the appearance of CD30+ anaplastic large cell 
lymphoma in that the cells are large with prominent nuclei and are CD30+. The 
distinction between the two types is based on the proportion of the atypical cells 
which exhibit a CD30+ immunophenotype. If the atypical cells are CD30+ then 
the lesion is type A; if a proportion are negative then the lesion is regarded as 
type C. In contrast, type B lesions present with smaller atypical lymphocytes 
which are CD30 negative. The immunophenotype of types A and C is equivalent 
to that of primary cutaneous anaplastic large cell lymphoma (CD4+, CD30+, TIA-
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1+ (T-cell cytotoxic intracytoplasmic enzyme antigen) and granzyme B +). In 
contrast, type B cells exhibit an immunophenotype similar to MF in that the 
atypical cells are CD2+, CD3+, CD4+, CD8-, CD30-, TIA-1- and granzyme B -. 
MF is a CTCL which involves mature T-helper cells (CD4+) (Wain et al 2005). 
However, approximately 5% of cases have a cytotoxic (CD8+) immunophenotype 
(Wain et al 2003). Characteristically, whether the atypical cells are CD4 or CD8+, 
the cells are commonly epidermotropic and have nuclei which appear cerebriform 
in shape.  
 
Clinically, MF is the most common CTCL with an annual incidence of 0.36 per 
100 000. MF presents with early stage disease (a patch), followed by plaque and 
then nodular tumour stages. Like LyP, MF commonly occurs in mature adults, 
although just as in LyP this is not exclusively so, as young adults and children 
can also be affected.  Atypical immunophenotypic profiles have recently led to the 
identification of specific subtypes of cases of MF and LyP (Bekkenk et al  2001 
and Flann et al  2006), the clinical significance of which remains unclear due to 
the rarity of their incidence. 
 
Evaluations of LyP and MF at the molecular level indicate that in 60-70% of LyP 
cases, it is possible to detect a clonal T cell receptor (TCR) gene rearrangement 
(TCR). In the case of MF a rearranged TCR is detected in the majority of lesions 
(Bekkenk et al 2001).  This indicates close synergy between these cutaneous 
lymphomas.  Currently there is significant interest in determining the proteins 
involved in activation pathways for CTCL, much of which has focussed on 
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activator protein 1 (AP-1), a dimeric transcription factor containing several 
members of proteins from the JUN (c-JUN, JUNB and JUND), FOS (c-Fos, FosB, 
Fra-1 and Fra-2), activating transcription factor [(ATF): ATF2, LRF1/ATF3, B-
ATF, JDP1, JDP2] and musculoaponeurotic fibrosarcoma [(MAF): c-MAF, MAFB, 
MAFA, MAFG/F/K and NRL] protein families.  Part of the research detailed here 
concerns evaluation of the degree of expression of some of these key molecules 
to determine which are expressed to a lesser or greater degree in relation to 
CTCL disease progression (Mao et al 2003). 
 
A similarity with the studies highlighted above on cutaneous lymphoma, this 
thesis also aims to evaluate activation antigens in malignant melanoma (MM), 
with particular relevance to their use in a diagnostic setting, to assist in 
demonstration of the myriad of histological appearances of MM. The study of 
activation antigen expression for both cutaneous lymphomas and MM forms the 
basis of this thesis. 
 
According to recent figures published by Cancer Research UK there are over 
92,000 new cases of skin cancer reported each year in the UK alone (2006) 
(Orchard 2006 and Anon Cancer Stats 2006). Non-melanoma cancer (NMC) 
accounts for around 81,600 cases with malignant melanoma (MM) accounting for 
10,400 cases. Skin cancer is now one of the most common cancer types reported 
in the UK. In terms of mortality rates MM represents the most significant skin 
cancer with over 2,000 deaths a year reported in the UK alone. 
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In most cases, clinical features of MM are quite characteristic, and although many 
MMs arise from an existing mole, the majority arise spontaneously. The primary 
trigger is ultra violet light, particularly UVB at a wavelength of 280-315 nm. 
Classical histological features of MM are well documented (Clark et al 1969 and 
Ackermann and David 1986), however atypical forms of these tumours can 
present with a myriad of features making diagnosis problematic. Many of these 
atypical forms of MM do not produce melanin and are broadly categorised under 
the heading of ‘amelanotic MM’. 
 
In such cases the role of immunocytochemical investigations is often essential to 
confirm the cell type of the tumour cells. In this regard the use of a host of 
melanocyte selective antibodies is employed, examples of which include HMB 
45, Melan A and tyrosinase. All three of these antibodies recognise antigens 
associated with melanin synthesis, which are indicative of melanocyte 
differentiation. HMB 45 recognises an antigen termed gp100 and was first 
described for use in a diagnostic setting by (Gown et al in 1986) . The Melan A 
protein is a product of the MART-1 gene, Chen et al (1996) and the antibody 
recognises a 22kDa doublet in melan-A mRNA positive melanomas (Jager et al 
1996). Tyrosinase is a cytoplasmic protein involved in melanocyte differentiation 
and is a key enzyme in melanin synthesis (Kauffmann 1998). Whilst these 
antibodies are effective for labelling conventionally histologically typed MM, with 
the majority of cases labelling positively (Orchard 2000) amelanotic variants of 
the tumour have variable to negative labelling profiles with these antibodies, 
making their diagnosis more problematic (Orchard and Wilson Jones 1994). 
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Immunocytochemistry is also vitally important in detection of metastatic MM 
deposits in lymph node material, and more significantly in sentinel lymph nodes 
where there may be only low numbers of cells to detect (Shani et al 2005). A 
sentinel lymph node is the first draining lymph node away from the primary site of 
the tumour. Successful detection of such deposits is currently a key prognostic 
indicator and one of the most effective means of staging MM. Although these 
markers are highly selective for melanocytes, none of them is specific marker for 
malignancy. They all label non malignant transformed melanocytes and thus can 
give positive results in normal moles or naevi (Blessing et al 1998). Application of 
a panel of antibodies is therefore advocated in the majority of cases and a 
diagnostic cocktail of these antibodies has also been introduced and evaluated 
(Orchard 2002), which has shown improved sensitivity for the detection of tumour 
cells in sentinel lymph nodes (Orchard 2003). In addition some cases of MM will 
present with extensive dermal melanosis making normal immunocytochemical 
detection methods highly problematic. In such cases confirming the nature of the 
atypical cells as either melanocytes or melanophages (melanin containing 
macrophages) can also be difficult (Orchard 1999 and 2007). The advent of a 
MM specific antibody which labels malignant melanoma cells only is still awaited 
for use on routinely fixed paraffin wax embedded tissue blocks. 
 
The studies documented here represent a significant body of research into 
mechanisms and pathogenesis of cutaneous malignant disease focussing on 
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cutaneous T cell lymphoma (CTCL) and MM. It encompasses investigations 
employing immunocytochemistry, real- time reverse transcriptase-polymerase 
chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH). The 
research objectives primarily focus on assessment of activation signal proteins 
involved with both tumour types, with particular reference to the quantifiable 
expression of activation molecules in relation to tumour stage. Consideration is 
given to unusual variants of these tumours with specific regard to 
immunophenotypic profiles and how this has enabled a more expansive 
understanding of classification of both tumour types. Possible implications of 
such research, in terms of patient management and prognostic outcome, are 
discussed. Emphasis is placed on laboratory-based problem solving and the 
review of scientific procedures and methodologies to improve practical assays 
and investigations. Through such activity a more tailored approach to evaluation 
of these tumours has been proposed and developed. The objective of this thesis 
is to employ the techniques and methods outlined here to meet two goals. 
1. To determine whether the antibodies employed can be used to increase 
accuracy of diagnosis.  
2. To evaluate whether any of these markers may increase our 
understanding of activation pathways of both MM and CTCL. 
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Chapter 2  Method Development 
 
St. John’s Institute of Dermatology is an internationally renowned reference 
centre for the study of cutaneous disease. The range of sometimes quite rare 
variations of tumour types has provided the opportunity to expand research 
potential and associated applications of diagnostic techniques. Use of such rare 
cases has also provided the opportunity for more in depth analysis and potential 
to develop a detailed understanding of disease progression and prognostic 
significance. 
  
Immunocytochemistry: Procedures and development 
 
The procedures used in this study represent two distinct technical processes, 
developed to better study cutaneous malignant disease.  Firstly, application of 
antibody markers previously untested on formalin fixed paraffin wax embedded 
tissue and secondly, development of tailored methods to enable dual antigen 
demonstration (double labelling) on the same section.  In the case of the AP-1 
protein families in particular, there has been little previous work on use of specific 
antibodies to these proteins on formalin fixed paraffin wax embedded tissue 
sections. The studies performed here have enabled generation of standardised 
working procedures, including full evaluation of dilution factors and incubation 
times for the primary antibodies and viability studies for use of each antibody. 
Evaluation of antigen retrieval procedures was also performed to establish 
optimum methodology and appropriate control material for each antibody tested.  
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For antigen demonstration it is generally accepted that frozen section material 
offers the best opportunity to demonstrate the widest range of antigens, as the 
tissue is unfixed and antigenic proteins are largely undenatured.  However, 
frozen tissue has the disadvantage of reduced morphological clarity coupled with 
tissue section deterioration. Preservation of section integrity is enhanced by 
fixation, but inadequate fixation leads to loss of antigenicity through the diffusion 
of antigens into surrounding tissue as a result of cell lysis and degradation in 
frozen sections.  
Fixation should ideally:- 
 
• Preserve the morphological appearance 
• Preserve the immunoreactivity of antigens 
• Prevent extraction of antigens during the immunohistochemical 
procedures 
• Not interfere with the subsequent antigen-antibody interactions 
• Enable antigenic epitopes to survive subsequent antigen retrieval 
 
The most widely used fixative in cell pathology is formalin. Modern day 
formulation of formalin is often 10% neutral buffered (NBF). Formalin remains the 
most popular fixative for the one simple reason that it provides acceptable 
standards of fixation whilst allowing the full scope of cellular pathology 
investigations to be undertaken, including retrospective molecular analysis on 
nearly all types of tissue samples. Post- fixation three-dimensional structure of 
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cell proteins is determined in great part by survival against protein denaturation, 
brought about by covalent bond formation between formaldehyde and amino 
groups present in the tissue. Formalin-induced cross-linking of amino acid side 
chains via methylene bridge formation also occurs, with subsequent changes in 
protein folding and structure. While some antigens remain unaffected by this 
process, others may be more susceptible to fixation and the overall result is loss 
of immunoreactivity due to masking of epitopes (Shi et al 2001). In general, 
because degree of cross-linking is proportional to time spent in fixative, tissue 
that has received prolonged fixation requires longer or more vigorous unmasking 
protocols. The issue of neutral pH for fixatives is important because acidic 
mixtures may induce undesirable changes to antigenic binding sites and 
therefore result in decreased sensitivity of any IMC procedure. 
All the tissues used in this thesis were fixed for 24 hours in NBF at room 
temperature. 
 
Following fixation, tissues were processed through to paraffin wax. Having 
optimised fixation, the next variable investigated was alcohol dehydration in 
tissue processing. It is now well documented that tissue processing temperatures 
and duration of dehydration and wax infiltration will all affect antigen preservation 
on tissue samples (Williams et al 1997). It is important to ensure that tissues are 
not processed at temperatures any higher than 60 º C, as higher temperatures 
not only affect preservation of antigenic epitopes, but may also result in 
destruction of tissue architecture. Antigen retrieval techniques rely on heat above 
60º C for very short periods of time therefore reducing detrimental effects. 
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Due to the many variables affecting extent of fixation-related cross-linking, it is 
necessary to find optimum treatment time and technique for each antigen. In this 
thesis this was achieved by considering a number of approaches involving 
unmasking antigen binding sites using either enzyme digestion methods 
employing trypsin or heat mediated antigen retrieval using a citrate buffer system 
at pH 6.0 and microwave oven heating to approximately 100º C. In the case of 
double labelling both methods were employed to demonstrate two different 
antigens on the same tissue section using two different coloured chromogens 
(Shani et al 2005). The IMC labelling technique employed throughout this thesis 
involved use of either a streptavidin biotin three step system (Dako- ChemMate 
HRP system) or in the case of double labelling, a dextran polymer system (Dako- 
Envision). 
 
Two of the publications submitted for consideration with this thesis include 
additional supportive data generated by others, using specialist techniques not 
routinely available in dermatopathology laboratories. These publications are listed 
below and the author duly acknowledges their contribution with thanks: 
1. Mao, X., Orchard GE*., Vonderheid EC., Nowell PC., Bagot M., 
Bensussan A., Russell-Jones R., Young BD., Whittaker SJ.  (2006). 
Heterogenous abnormalities of CCND1 and RB1 in primary cutaneous T-
cell lymphomas suggesting impaired cell cycle control in disease 
pathogenesis. Journal Investigative Dermatology, 126, pp. 1388-1395. 
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* indicates joint first author 
2. Mao X, Orchard G*, Mitchell JT, Oyama N, Russell-Jones R, Vermeer 
MH., Willemze R., van Doom R., Tensen CP., Young BD., Whittaker SJ. 
(2008). A genomic and expression study of AP-1 in primary cutaneous T-
cell lymphoma: evidence for dysregulated expression of JUNB and JUND 
in MF and SS. Journal of Cutaneous Pathology, 35, pp. 899-910. 
* indicates joint first author 
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Chapter 3  Summary of research 
 
For the purpose of this thesis data compiled from the submitted publications 
covers four distinct but related areas of research: 
 
1. MF and LyP with CD56 expression 
2. AP-1 CTCL findings 
3. IMC techniques and developments 
4. MM IMC with double labelling 
 
1. Cell lineage markers in MF and LyP 
Two of the selected publications included with this thesis comprise this section: 
 
1. Wain EM, Orchard GE*, Mayou S, Atherton DJ, Misch KJ, Russell-Jones 
R. (2005). Mycosis fungoides with a CD56 positive immunophenotype, 
Journal of the American Academy of Dermatology, 53, pp.158-63. 
 
2. Flann S, Orchard GE*, Wain EM, Russell-Jones R (2006). Three cases of 
lymphomatoid papulosis with a CD56 positive immunophenotype, Journal 
of the American Academy of Dermatology, 55, pp. 903-906. 
* Indicates joint first author 
These publications report expression of CD56 (neuronal cell adhesion molecule), 
an antigen which is expressed by natural killer cells and cytotoxic T cells in three 
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cases each of MF and LyP. A compilation of the IMC findings from both 
publications is summarised below:- 
 
CASE CD2 CD3 CD4 CD8 CD30 Beta F1 Granzyme 
B 
TIA-1** LMP-1* CD56 
1. LyP 1 + + - + - N/A N/A + N/A + 
2. LyP 2 + + - + + + + + N/A + 
3. LyP 3 + + - + + + + + N/A + 
4. MF 1 + + - + - N/A - + - 
+ 
5. MF 2 + + - - - N/A + + - + 
6. MF 3# + + - + -/+ N/A + + - + 
 
Table 1: Summary of IMC findings for independently assessed 3 cases 
of LyP and 3 cases of MF:   
*LMP-1 = Epstein-Barr virus latent membrane protein, **TIA-1 = T cell intracellular antigen, N/A = lack of material for 
assessment. # Case MF3 had two lesions - one poikiloderma, the other tumour stage. Poikilodermas are a heterogenous 
group of dermatoses which are characterized clinically, by erythema, mottled pigmentation and, at a later stage, epidermal 
atrophy. In this context they represent a stage in evolution of early MF. The designation -/+ for CD-30 expression in this 
case indicates poikiloderma lesion negative, tumour lesion positive 
 
The expression profiles indicate pan T cell marking with CD2 and CD3, cytotoxic 
CD8 labelling for 5/6 cases, with conversely negative findings for CD4. Cytotoxic 
granules labelled in all cases with TIA-1 and in 4/5 cases with Granzyme B. The 
Beta F1 labels the beta chain of alpha/ beta chain of the T cell receptor (TCR) 
and was positive in the two cases of LyP examined. Material was not available for 
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all cases to be studied. However, beta F1 expression is commonly seen in cases 
of the majority of CTCL. The alternative expression of a gamma/delta TCR is 
extremely rare. Expression of CD30 was positive in LyP type A lesions (cases 2 
and 3) and in tumour stage (case 3) MF lesion. CD30 expression in this context 
indicates lymphocyte activation. In cases of tumour stage MF positive CD30 
expression can be indicative of systemic spread of CTCL from skin to lymph 
nodes. LMP-1 was negative in all cases of MF examined. All cases examined 
expressed CD56, although incidence of CD56 expression in the literature in 
cases of MF and LyP is rare. These data suggest that there may be a subset of 
CD56+ MF and LyP. 
 
2. AP-1 CTCL findings 
This section is comprised of a series of four publications concerning expression 
of AP-1 proteins in CTCL (MF and SS), CD30 positive cutaneous large cell 
lymphoma and B cell lymphoma.  
 
1. Mao, X., Orchard GE*., Vonderheid EC., Nowell PC., Bagot M., Bensussan 
A., Russell-Jones R., Young BD., Whittaker SJ. (2006). Heterogenous 
abnormalities of CCND1 and RB1 in primary cutaneous T-cell lymphomas 
suggesting impaired cell cycle control in disease pathogenesis. Journal of 
Investigative Dermatology, 126, pp. 1388-1395. 
* Indicates joint first author 
2. Mao, X., Orchard G., Mitchell JT., Oyama N., Russell-Jones R., Vermeer 
MH., Willemze R., van Doom R., Tensen CP., Young BD., Whittaker SJ.. 
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(2008). A genomic and expression study of AP-1 in primary cutaneous T-cell 
lymphoma: evidence for dysregulated expression of JUNB and JUND in MF 
and SS. Journal of Cutaneous Pathology, 35, pp. 899-910. 
 
3. Mao, X and Orchard, G*. (2008). Abnormal AP-1 expression in primary 
cutaneous B-cell lymphomas. British Journal of Dermatology, 159, pp. 145-
51. 
 
4. Mao, X.,Orchard GE*, Russell-Jones R.,Whittaker S.. (2007). Abnormal 
activator protein 1 transcription factor expression in CD30-positive cutaneous 
large-cell lymphomas. British Journal of Dermatology, 157, pp. 914-21. 
* Indicates joint first author 
 
These studies set out to attempt to establish which AP-1 proteins were 
significantly expressed in these groups of lymphomas, and thus indicate which 
may have a role in lymphoma pathogenesis (Mao et al 2006,2007, 2008a and 
Mao and Orchard 2008b). The table below indicated overall findings from this 
series of papers. 
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Table 2 Summary of immunohistochemical data on AP-1 protein 
expression in CD30 positive lymphomas, CTCL and B cell lymphomas. 
C-ALCL=Cutaneous anaplastic large cell lymphoma, LyP A = Lyphomatoid papulosis type A, TMF = Transformed MF, SS 
= Sezary Syndrome, MF = Mycosis fungoides, HL = Hodgkin’s lymphoma, PCMZL = Primary cutaneous marginal zone B 
cell lymphoma, PCFCL = Primary cutaneous follicular cell lymphoma, PCLBCL-LT = Primary cutaneous large B cell 
lymphoma- leg type, PCBCL = Primary cutaneous B cell lymphoma. Samples were considered positive when the antigen 
in question was expressed by 50 -100% of tumour cells, indicating expression of these antigens by the atypical population 
of cells within the tumour areas. 
 CD30 POSITIVE CTCL B-CELL LYMPHOMA 
Signalling 
molecules 
and trans-
cription 
antibodies 
C-ALCL 
% 
POS 
LyP A 
% 
POS 
TMF 
% 
POS 
SS 
% 
POS 
MF 
% 
POS 
HL 
% 
POS 
PCMZL 
% 
POS 
PCFC 
% 
POS 
PCLBCL-T 
% 
POS 
PCBCL 
% 
Pos 
C-JUN 10 2.7 38 9 22 50     
JUNB 44 11 50 55 9 100     
JUND 100 48 75 21 70 100 56 86 83 50 
C-FOS 22 10 12.5 6 30 29   17  
RAF-1 33 2.7   4.3    33  
P44/42 
MAPK 
90 2.7 89 84  100     
PAK 1       22 14 50  
CD30    3 13      
CCND1/B
CL1 
70   50 45  44 57 67 100 
C-JUN       11 14   
ERK1/2 
MAPK 
   24       
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The cumulative data indicate that dysregulated expression of both JUNB and 
JUND occurs in CTCL. with JUNB over expressed to a greater extent in SS 
compared to MF and conversely JUND over expressed to a greater extent in MF 
compared to SS. In the case of CD30 positive lymphomas the findings are similar 
to the majority of lymphomas over expressing JUND and to a lesser extent JUNB.  
In contrast, AP-1 protein expression in B cell lymphomas indicates upregulation 
of JUND, CCND1 and PAK1 with down regulation of JUNB in PCBCL. These 
findings would suggest that the AP-1 activation mechanisms, between CTCL and 
B cell lymphomas have differences, the significance of which remains to be full 
elucidated. 
 
3. Immunocytochemical techniques and developments 
 
This section of results reflects the technical and practical input of acquired 
knowledge gained throughout the preparation for this thesis. The two publications 
comprising this section were invited reviews. 
 
1) Orchard, G. (2006). Immunocytochemical techniques and advances in 
dermatopathology. Current Diagnostic Pathology, 12, pp. 292-302. 
 
2)  Orchard, G. (2008).  Detecting antigenic epitopes using 
immunocytochemistry in tumour pathology – is it really all about 
sensitivity? Immunocytochemistry, 6, (3), pp.116-118. 
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The first was intended to inform of the scope of immunocytochemical techniques 
applicable within the field of dermatopathology (Orchard 2006).  It reflects the 
author’s acquisition of knowledge across the length and breath of investigative 
IMC techniques applicable to the field of dermatopathology. This encompassed 
signal amplification dextran polymer based labelling systems, immunogold 
methodologies for demonstration of antigenic epitopes at the ultrastructural level, 
immunoflourescence applications in evaluation of autoimmune blistering diseases 
and increasing importance of fully automated IMC staining procedures.  The 
second publication was based on the need to inform on the issue of IMC assay 
sensitivity (Orchard 2008). Whilst preparing this thesis and dealing with tumour 
pathology it became apparent that antigenic demonstration in tumour pathology 
was not always uniform, but could be variable. This is commonly seen with MM 
where many activation antigens are strongly expressed at the dermal/epidermal 
junction but are much more variably expressed in dermal deposits of cutaneous 
disease. This labelling profile is not always governed by sensitivity of the assay 
but may also reflect lack of protein expression at light microscope level. In a 
wider perspective and as an assessor for UKNEQAS immunocytochemistry for 
some years, it was apparent that many scientists have a ‘blinkered’ view of this 
concept. The publication was intended to be informative and to encourage 
debate.
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4. Malignant melanoma immunocytochemistry using double labelling 
Of the two publications relevant to this section, one involved collaborative work 
with St. John’s Photobiology Department, assessing effects of cutaneous 
photodamage.  
1) Orchard, G. (2004). ‘Dying for a tan’-immunocytochemistry in the study of 
cutaneous photodamage and malignant melanoma. Immunocytochemistry, 
3, pp. 45-46. 
 
Studies of early signs of damage to epidermal keratinocytes caused by ultra 
violet light exposure can be measured by use of immunocytochemical markers 
for specific antigenic epitopes (Orchard 2005). Assessments involved using 
volunteers of skin type 1 and 2 (most susceptible to sun damage). There is an 
internationally recognised classification of six skin types:  
 
Skin Types 
Type 1 White skin that never tans, but always burns 
Type 2 White skin that burns initially but tans with difficulty 
Type 3 White skin that tans easily and rarely burns 
Type 4 White skin that never burns and always tans (generally 
Mediterranean or oriental skin type) 
Type 5 Brown skin (Asian skin type) 
Type 6 Black skin (African and Caribbean skin type) 
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The normal process of skin aging is a chronological effect that happens to all 
individuals. These chronological changes are produced as a result of a multitude 
of factors including environment, diet, social activity, smoking for example. In 
order to determine the effects of ultra-violet light on photo sensitive skin types 
(types 1 and 2) it is important to study these effects on skin that is normally 
protected from the sun - buttock skin being the most commonly evaluated. The 
evaluations can then also be performed on sun exposed skin, generally forearm 
skin. These two sites can then be compared following controlled ultra-violet 
exposure. 
Each individual had a different dose of UV that produced an erythema -  
reddening of the skin surface. In effect this represents  mild sunburn. In order to 
determined minimal erythema dose (MED), the 24 hour perceptible MED for each 
individual used was determined by a geometric exposure series. Biopsies were 
then performed on the volunteers immediately after exposure to 0. 0.5, 1, 2 and 3 
times this MED and then was repeated again at 12 and 24 hour intervals 
following UVR administration. Immunocytochemistry was then performed using 
antibodies to p53, thymine –dimers, Bcl-2, MIB-1 and CD1a. These antibodies 
then allowed key evaluations of measuring effects of photodamage. Specifically:  
p53 and thymine dimers are indicative of DNA damage in affected keratinocytes 
(Young et al 2007). The Bcl-2 proto-oncogene product inhibits apoptosis induced 
by various stimuli and is constitutively expressed in basal keratinocytes of normal 
skin epidermis, but has been shown to be reduced in rat skin following UV 
exposure (Iwasaki et al 1996). MIB-1 enables assessment of keratinocyte 
proliferation levels following photodamage and CD1a is a marker of Langerhans 
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cells. The Langerhans cell is the immuno-competent cell of the epidermis and is 
known to be highly photophobic (Young et al 2007).  Using image analysis, 
quantifiable cell counts of positively stained cells could be determined. 
 
The data revealed statistically significant increase in p53 expression, thymine 
dimer formation and MIB1 expression directly following administration of UVR but 
no significant change in BCL-2 expression was noted. This is explained by the 
fact that immediately following the administration of UVR there is DNA damage 
as demonstrated with p53 and thymine dimmer formation, fairly quickly after this, 
damaged keratinocytes are then driven into the cell cycle to replenish the 
epidermal compartment with viable replacement cells, this is demonstrated by 
increased expression of MIB1. CD1a data revealed  significant reduction in 
Langerhans cell counts within the epidermis following UVR exposure. Within 24 
hours of UVR exposure levels of p53, thymine dimer, MIB1, proliferation levels 
were reduced and Langerhans cells gradually returned to repopulate the 
epidermis (Orchard G, 2004).  
 
The second paper submitted here concerns development and application of a 
novel procedure for characterisation of MM. 
 
2) Sahni, D. Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones. R. 
(2005). The use of LYVE-1 antibody for detecting lymphatic involvement in 
patients with malignant melanoma of known sentinel node status. Journal 
of Clinical Pathology, 58, pp. 715-721. 
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The objective was to double label lymphatic vessels and MM cells in primary 
cutaneous MM cases for which a positive sentinel lymph node (SLN) assessment 
had been established from routine diagnostic investigations (Shani et al 2005). 
This could then be compared to the same number of SLN negative assessments 
as a control group. The aim was to establish whether tumour cells identified 
within lymphatics could be used as a replacement for SLN status. In the SLN 
negative group, tumour cells were only identified in 1 out of 18 cases compared 
to 5 of 18 in the SLN positive group, there was however no significant difference 
in lymphatic counts between SLN negative and SLN positive cases. These data 
would seem to Indicate that the use of LYVE-1 in conjunction with S100 protein, 
can help detect melanoma cells within lymphatics, but as yet is unreliable in 
predicting melanoma metastasis. 
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Chapter 4 Discussion  
 
Skin cancer is a clinically defined disease where assessments of skin lesions can 
be highly detailed and in some respects is therefore almost unique when 
compared to other organ specific pathologies, which generally rely on 
sophisticated equipment for clinical assessment. Clinical appraisal by the human 
eye and the option to touch and feel such lesions has significant advantages. 
This concept is so well defined in dermatology that clinically defined stages of 
cancer progression can be attributed to specific microscopic findings, for example 
the clinical and pathological criteria of patch, plaque and tumour stages of MF. 
This is the case for both CTCL and MM, where very clearly defined clinical 
appearances guide microscopic differential diagnosis of a benign, dysplastic or 
malignant melanocytic lesion (Willemze et al 2005 and Ackermann and David 
1986).   
 
Why then in the case of CTCL do some patients simultaneously present with 
more than one type of lymphoma? There is clearly a link between LyP and other 
forms of CTCL with LyP representing an entity which could provide the key to this 
question. There is evidence from a wide range of sources to support the notion 
that LyP is a true lymphoma. At  light microscope level, LyP demonstrates 
cytomorphological features of atypia as demonstrated by type A, B and C cells 
(Basarab et al 1998). In addition, there are accompanying IMC findings such as 
persistent CD30 positivity, which although not an absolute marker for malignancy, 
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in the context of CTCL is quite often an associated finding (Bekkenk et al 2000). 
TCR studies have revealed rearrangements in 60- 70% of cases (Willemze et al 
2005 and Weiss et al 1986). DNA analysis by flow cytometry has shown 
hyperdiploidy, tetraploidy and hypertetraploidy (Lange Wantzin et al 1983). There 
is also evidence of an abnormal karyotype in cytogenetic studies of skin biopsies 
(Espinoza et al 1985) and evidence of metastatic potential within LyP cases has 
been suggested by studies on down regulation of transforming growth factor beta 
(TGF-β) receptors on LyP atypical cells (Kadin et al 2001). Collectively all these 
data supports the notion that LyP is a lymphoma.  Evidence from the studies 
presented in this thesis highlights that some cases of LyP and MF express CD56, 
suggesting a potential link with a cytotoxic CD8 positive immunophenotype in 
rare cases, since nearly all CD56 positive cases were also CD8 positive (Wain et 
al 2005 and Flann et al 2006). This finding may have a bearing on prognostic 
outcome since evidence from data on CD56 positive subcutaneous pannicultis-
like T cell lymphoma and blastic natural killer cell lymphoma indicates worsening 
prognosis (Jaffe et al 2001). These papers supported our earlier findings of CD8 
positive cases of juvenile MF(Wain et al 2003).  MF is generally a disease of 
older patients, but occasionally occurs in children, with over 95 % of such cases 
having immuno phenotype of CD4 (T/helper) positive.  Cases of MF in children 
are unusual. This study arose because of an initial case presenting in a child who 
was CD8 positive a rare phenotype for MF.  Molecular data assessing 
rearrangement of the TCR and using PCR to detect single stranded 
polymorphism, indicated that the child did indeed have a gene rearrangement 
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confirming the malignant nature of the disease, with further subsequent skin 
lesions confirming the original findings. This prompted a review of all the 
childhood cases of MF seen at St. John’s, which covered decades of data. 
Evaluation of 34 cases of juvenile MF was performed. The study revealed several 
additional cases of CD8 positive MF (38%) of those cases examined.  
Occurrence of CD8 positive phenotype in juvenile cases of MF seemed far more 
prevalent than the overall data would seem to suggest. The patient’s subsequent 
management was reviewed to determine whether these patients performed any 
better or worse prognostically (Wain et al 2003). Overall disease free survival 
rates were similar to adult onset disease. However, although this particular study 
was the biggest by far to be assessed, actual numbers were still quite low. 
However the data indicated that the finding of CD8 positive expression in juvenile 
cases of MF was far more prevalent than had been previously suggested. Future 
studies with detailed follow up data may enable more specific treatment and 
patient management regimes to be established earlier in the disease pathway. 
In the case of LyP 80-90% of patients present with papulonodular lesions which 
are either singular or multiple, which self heal leaving a scar. The notion of 
spontaneous resolution of malignant lesions is not unique in cutaneous 
pathology. Cases of MM which resolve spontaneously due to a potent host 
response are well documented in the literature (Shai et al 1994). It is also the 
case that CTCL can run a relatively benign course with several stages of 
dormancy throughout the clinical progression of the disease. It could be the case 
that LyP may, in fact, be an indicator of immune dysfunction, which then allows a 
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similar but independent lymphoproliferative disease to breach the immune 
surveillance mechanisms. 
In the case of MM the use of markers of proliferation is widely employed to help 
distinguish dysplastic from malignant melanocytic lesions. Malignant lesions in 
both CTCL and MM have higher proliferative cell counts. This is particularly 
useful in MM since proliferation rates of over 10% of the melanocytic cell 
population within any given lesion is more indicative of malignant transformation 
over a stable, benign state.  For this purpose the antigen Ki67 and its antibody 
MIB-1 are often employed and the use of antibodies raised against the AP-1 
family of proteins, may be complementary in this setting. It is well documented 
that this family of proteins is implicated in regulatory pathways of proliferation, 
differentiation, cell maturation, apoptosis, cell migration and transformation 
(Vesely et al 2009).  What is also clear from the studies documented in this 
thesis, at light microscope level, Affymetrix expression microarray, real-time 
reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in 
situ hybridization (FISH) studies, is that certain proteins of this family are 
expressed at high levels. The data accumulated indicated that JUNB and JUND 
are over expressed in the majority of cases of Sezary syndrome and mycosis 
fungoides (Mao et al 2003, and 2008). Similarly, both phosphorylated and total 
extracellular signal-regulated kinase (ERK) 1and 2 mitogen-activated protein 
kinase (MAPK) proteins were increased (Mao et al 2008). This suggests that 
deregulation of AP-1 expression in cutaneous T cell lymphoma is characterized 
by aberrant expression of JUNB, and to a lesser extent JUND. These data 
suggest that JUNB is a significant transcriptional factor in the development of 
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CTCL.  Possibly resulting from genomic amplification and subsequent activation 
of ERK 1 and 2  MAPK in cutaneous T cell lymphoma (Mao et al 2008). 
Immunocytochemical data from this study also demonstrated that JUND 
expression can be seen in non tumour cell lymphocytes, whereas JUNB 
expression is much less in such cells. This would seem to suggest that JUND is 
mainly involved in lymphocyte proliferation, whereas JUNB is involved in 
lymphocyte transformation and lymphoma progression or that they are mutated in 
some way. In studies of CD30 positive CTCL no direct correlation was seen 
between JUNB expression and CD30 expression. In LyP it was observed that 
although JUND was expressed widely irrespective of the histological sub type of 
LyP (A,B or C), JUNB was not expressed in the majority of skin lesions. However 
it was expressed at high levels in cutaneous anaplastic large cell CD30 
lymphomas (Mao et al 2007).  
 
In comparison, primary cutaneous B cell lymphoma (PCBCL) revealed loss of 
expression of JUNB, and increased expression of JUND in the majority of lesions 
studied. In addition it was possible to demonstrate increase in cyclin D1 (CCND1) 
expression and also PAK 1 which promotes dis-assembly of stress fibres and 
focal adhesions and functions as a dominant oncogene, expressed in a variety of 
cancers other than cutaneous B cell lymphoma (Mao et al 2008). There is 
association between CCDN1 and PAK1, in that expression of both proteins is 
upregulated in liver cancer (Parekh and Rao 2007) and the PAK1 gene maps to 
human chromosome 11q13q14 (Bekri 1997), which is close to the location of 
CCDN1 (11q13). It may well be that increased expression of PAK1 and CCDN1 
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protein expression relates to a copy number gain of chromosome 11 which is 
documented in cutaneous B cell lymphoma (Wiesner et al 2005). Taken 
collectively, these data would indicate differing activation pathways between 
CTCL and PCBCL. 
 
It seems likely that in de-regulation of AP-1, expression occurs in CTCL as a 
result of specific chromosomal amplification of JUNB, translating into an over 
expression of JUNB at the protein level.  It is known that JUNB has a specific role 
in T cell activation, binding to the IL-4 promotor and promoting Th2 differentiation 
and expression of Th2 cytokines (Li et al 1999 and Voice et al 2004).  It seems 
likely therefore that the Th2 cytokine expression profile seen in Sezary syndrome, 
namely IL-4 and IL-10, may be a direct consequence of JUNB over expression. 
(Voice et al 2004) 
 
As a result of the observations made in the authors’ publications submitted for 
this thesis, coupled with a growing interest and involvement in application of 
immunocytochemistry in the pathology setting, the author has been approached 
and assigned as an assessor with UKNEQAS for immunocytochemistry 
(UKNEQAS ICC). UKNEQAS ICC represents the recognised quality control body 
for use of immunocytochemistry nationally. What became apparent in this role 
was the misunderstanding of why antigens associated with certain tumours were 
not universally expressed in all cases. What was being perceived as a lack of 
sensitivity for detection of certain antigens was in fact more concerned with 
reduced expression of such antigens at light microscope level. This issue 
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becomes more apparent when dealing with metastatic deposits, especially if the 
antigens concerned are related to activation antigens. These observations relate 
to molecular and cell protein expression of any given tumour and do not always 
relate to substandard immunocytochemistry procedures or more specifically 
decreased sensitivity. The use of appropriate positive controls is paramount to 
assess quality, since it represents the known and established level of sensitivity 
for a given antigen in a given assay. 
 
There were two over-arching aims to the studies included in this thesis, the first of 
which was to establish the value and application of a small panel of 
immunocytochemical antibodies against activation antigens, for the study of 
CTCL and MM. The majority of the antibodies discussed within this thesis had not 
previously been tested for use on formalin fixed paraffin embedded tissue 
sections and, following extensive development work to ensure viability of the 
antibodies for use, the data compiled represents novel and incisive findings. The 
second aim concerns development of an understanding of the significance of the 
expression of certain activation antigens in terms of the tumour pathway in CTCL 
and MM. 
 
The papers and data presented here have formed the basis of two streams of 
further continuing investigation. 
 
1) From the data compiled on activation antigen expression in MM,  
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the author, in conjunction with UKNEQAS ICC, is compiling results of an 
international trial to evaluate use of HMB 45 and Melan A for MM  
diagnosis.  MM cases of primary cutaneous, secondary cutaneous and nodal 
metastatic MM have been selected with a total of four assessments performed 
over a one year period. For each assessment a different type of MM was chosen 
from the cases above.  These cases have been circulated to over 800 
laboratories for each assessment throughout the UK and abroad with the request 
that they perform staining for either HMB45 or Melan A, the two most common 
monoclonal antibodies used for MM diagnosis (Gown et al 1986 and Orchard 
1998). On the return of these slides to UKNEQAS ICC, the author along with a 
panel of experts has scored all these returns in terms of sensitivity and specificity 
of staining. All participants have provided detailed information on the techniques 
performed. From these data, analysis of methodology and performance will be 
extrapolated. These data will allow objective assessment of the best clones to 
use and also the best techniques to employ to maximise  sensitivity of the assay. 
Inclusion of metastatic cases which are known to be variable in terms of 
expression of these activation antigens will allow the author  very good insight 
into the nature of expression of activation antigens across the length and breadth 
of histological presentations of MM. 
 
2) Extending from the CTCL AP-1 expression studies, the author is currently 
pursuing studies to determine whether use of JUNB will be more beneficial in 
helping establish final stage of transformation in cases of MF. Transformation is 
the stage at which the patient’s skin disease becomes systemic and represents 
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the patient’s final stage before they succumb to it. Currently MF is negative for 
the expression of CD30 until it reaches end stage disease at which point the 
tumour cells often express CD30. This is a useful observation used to suggest 
imminent likelihood of transformation, but it is not however absolute.  Evaluation 
of known cutaneous end stage disease cases of MF for expression of JUNB may 
prove useful in conjunction with CD30 expression, and clinical outcome 
observations for prediction of transformation in MF patients. If this theory is 
proved correct, JUNB may well be a useful prognostic tool within this area of 
pathology.
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